FDA Investigator Rory K Geyer

Rory K Geyer has conducted inspections on 49 sites in 4 countries as of 08 Sep 2014. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
49
Last Inspection Date:
08 Sep 2014
Investigator Role:
FDA Investigation Participant
Redica ID:
100008940
Countries of Inspections:
United States of America, Japan, Taiwan, Colombia
FDA Investigators that have inspected at least one site in common with Rory K Geyer:
Abby E Pelletier, Aireen V Mendoza, Alan R Condon, Alice C Silva, Alicia M Mozzachio, Allison A Rodriguez, Almaris N Alonso, Alois P Provost, Amber G Wardwell, Amy C Jordan, Andrew M Barlow, Ann Marie Montemurro, Anna Lazar, Anne E Carpenter, Anne Marie Dubrey, Annet R Rajan, Anthony C Warchut, Anthony W Thomas, Arie C Menachem, Ashley M Whitehurst, Atricia L Irons, Azza Talaat, Barbara G Swan, Bijoy Panicker, Bo Chi, PhD, Brenda P King, Byungja E Marciante, Carla A Norris, Carla C Cummins, Carla C Tuite, Carlos Chavez, Charles A Snipes, PhD, Charles I Ann, Charles M Edwards, Charles R Bonapace, PhD, Charlotte Hinkle, Chiang Syin, PhD, Constance Desimone, Courtney N Long, Cynthia Jim, CSO, Cynthia Whitmarsh, Daniel L Zheng, Darin S Wiegers, Daryl A Dewoskin, David P Vanhouten, Deborah J Parris, Dell S Moller, Dien N Nguyen, Divek R Jumani, Dolores Harper, Donna J Clevenger, Dorothy W Lee, Douglas S Joslin, Dr. Abhijit Raha, PhD, Dr. Barbara D Paul, PhD, Dr. Mark J Seaton, PhD, Dr. Robert C Horan, MD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Edmund F Mrak, Jr, Ellen P Madigan, Emily J Schramm, Frank P Hurst, Gary J Hagan, George J Flynn, George T Allen, Jr, Gerard D Difiore, Helen B Ricalde, Jacqueline Mdiaz Albertini, Jawaid Hamid, Jianming Li, Joan A Loreng, John A Sciacchitano, John P Mistler, Jonathan G Matrisciano, Jose M Cayuela, Jose R Hernandez, Joseph H Procopio, Jr, Joshua P Wireman, Joyce A Kellett, Julie D Bringger, Justin A Boyd, Justine M Corson, Kalavati Suvarna, PhD, Karen A Briggs, Karen Mcnabb Noon, Katherine D Adams, Kenneth H Williams, Kent A Conforti, Kham Phommachanh, Khoa Nathanv Tran, Laura L Staples, Lauren M Lawrance, Laurie B Frazier, LCDR Debra Emerson, Leo B Zadecky, Leonard H Lavi, Li Yun Huang, Lillie D Witcher, Lori M Newman, LTJG Bradley E Benasutti, Luis A Dasta, Margaret E Walsh, Margaret M Sands, Mariza M Jafary, Mark C Lookabaugh, Mark E Parmon, Marlene L Davis, Martin J Guardia, Mary Jeanet Mcgarry, Maryam Tabatabaie, Matthew C Watson, Matthew D Silverman, Maura Rooney, Maya M Davis, Megan A Haggerty, Meisha Waters, Meredith L Miller, Michael A Charles, Michael J Casey, Michael J Pasternak, Michael P Anthony, Michael Serrano, Michele L Obert, Michelle M Noe Varga, Michelle Yclark Stuart, Mihaly S Ligmond, Milva E Melendez Perales, Nichole B Murphy, Pamela L Lee, Pamela L Ogonowski, Paraluman S Leonin, Paul L Bellamy, Paul P Geraci, Paula A Trost, Paula M Laplant, Peter C Chow, Philip Kreiter, Prabhu P Raju, Qin Xu, Ramon E Martinez, Raymond Kent, Reba A Gates, Richard A Abate, Richard B Mcaroy, Richard H Penta, Richard L Friedman, Richmond K Yip, Robert J Martin, Robert O'brian, Roman T Drews, PhD, Sara M Onyango, Sean R Marcsisin, Sharon K Thoma, PharmD, Sherry M Nisson, Shirley S Wen, Simone E Pitts, Slater K Bartlett, Stacey S Degarmo, Stephen C King, Stephen C Smith, Stephen D Brown, Stephen R Souza, Sunita Pandey, Susan W Ting, Susanne M Richardson, MS RAC, Ted L Anderson, Teddy Tom, Teresa I Navas, Thomas J Arista, Thomas W Nerney, Truong Xuan Nguyen (Andy), Victor J Gangi, Wayne E Seifert, Ying Xin Fan, PhD, Ze Peng

Rory K Geyer's Documents

Publish Date Document Type Title
December, 2011 FDA 483 Millennium Pharmaceuticals, Inc. - Form 483, 2011-12-16
April, 2010 FDA 483 Lyne Laboratories, Inc. - Form 483, 2010-04-05
March, 2011 FDA 483 Safecor Health, LLC - Form 483, 2011-03-07
April, 2012 FDA 483 Nisshin Pharma Inc. - Form 483, 2012-04-12
November, 2012 FDA 483 Ameridose, LLC - Form 483, 2012-11-09
August, 2009 FDA 483 Millennium Pharmaceuticals, Inc. - Form 483, 2009-08-05
May, 2010 FDA 483 ISP Freetown Fine Chemicals Inc. - Form 483, 2010-05-04
June, 2012 FDA 483 US Generics Program - Form 483, 2012-06-22
November, 2009 EIR Armstrong Pharmaceuticals, Inc. - EIR, 2009-11-13
June, 2012 EIR US Generics Program - EIR, 2012-06-22
August, 2010 FDA 483 Fresenius Medical Care Holdings, Inc. - Form 483, 2010-08-06
September, 2014 FDA 483 Genzyme Corporation - Form 483, 2014-09-25
December, 2012 FDA 483 Polycarbon Industries, Inc. - Form 483, 2012-12-20
January, 2010 FDA 483 Braintree Laboratories, Inc. - Form 483, 2010-01-22
October, 2010 FDA 483 Genzyme Corporation - Form 483, 2010-10-22
March, 2012 EIR ScinoPharm Taiwan, Ltd. - EIR, 2012-03-29
July, 2009 FDA 483 The Dodge Company, Inc. - Form 483, 2009-07-02
June, 2009 FDA 483 Cambridge Isotope Laboratories, Inc. - Form 483, 2009-06-18
January, 2013 FDA 483 BFS Pharma, Inc. - Form 483, 2013-01-17
March, 2012 FDA 483 ScinoPharm Taiwan, Ltd. - Form 483, 2012-03-29
October, 2011 FDA 483 Genzyme Corporation - Form 483, 2011-10-27
February, 2010 FDA 483 Lapuck Laboratories, Inc. - Form 483, 2010-02-09
July, 2011 FDA 483 Lantheus Medical Imaging, Inc. - Form 483, 2011-07-18
August, 2011 FDA 483 Pace Analytical Life Sciences, LLC - Form 483, 2011-08-16
May, 2011 FDA 483 Lonza Biologics, Inc. - Form 483, 2011-05-06
November, 2009 FDA 483 Armstrong Pharmaceuticals, Inc. - Form 483, 2009-11-13
April, 2009 FDA 483 CBI - Form 483, 2009-04-30

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more